SRA 141

Drug Profile

SRA 141

Alternative Names: AS-141; PNT-141; SRA141

Latest Information Update: 31 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CrystalGenomics; SBI Biotech
  • Developer Carna Biosciences; SBI Biotech; Sierra Oncology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cdc7-ASK kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 27 Feb 2018 Sierra Oncology plans to file an IND application for Cancer in the second half of 2018
  • 27 Feb 2018 Sierra Oncology plans a phase I/II trial in Colorectal cancer
  • 09 Jan 2017 ProNAi Therapeutics is now called Sierra Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top